Status:
UNKNOWN
Non-invasive Diagnostic Model of Liver Fibrosis Associated With NAFLD and Prediction of Prognosis
Lead Sponsor:
Beijing Municipal Administration of Hospitals
Conditions:
Non-alcoholic Fatty Liver Disease
Eligibility:
All Genders
18-75 years
Brief Summary
In a retrospective study, 200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fatty liver fibrosis have been identified for pathological diagnosis of liver histology and ex...
Detailed Description
This topic is a prospective - retrospective observational study including two parts, retrospective and prospective: in a retrospective study, 200 patients with non-alcoholic fatty liver disease, fatty...
Eligibility Criteria
Inclusion
- patients with non-alcoholic fatty liver, fatty liver hepatitis and fatty liver fibrosis: all meet the diagnostic criteria of China's "Guidelines for the Prevention and Treatment of Non-alcoholic Fatty Liver Diseases (2018 Update)";
- Age between 18 and over 75;
- patient were never treated with no hormones and / or immunosuppressants and other liver protection drugs.
Exclusion
- combined with hepatitis virus infection;
- autoimmune liver disease;
- HIV infection;
- long-term alcohol abuse and / or other liver damage drugs;
- mental illness;
- Evidence of liver tumors (liver cancer or AFP \> 100 ng/ml);
- decompensated cirrhosis;
- Serious diseases such as heart, brain, lung, kidney, etc. can not participate in long-term follow-up.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03842748
Start Date
January 1 2018
End Date
December 30 2021
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100015